Αρχική World News Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs to...

Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs to Improve Patient Outcome Following Immune Checkpoint Inhibitor Therapy

Patients receiving immune checkpoint inhibitor (ICI) treatment who developed a rheumatic immune-related adverse event (irAE) displayed symptoms that resembled classical rheumatic and musculoskeletal diseases (RMDs), but seldom fulfilled their classification criteria mainly due to dissimilar laboratory characteristics. These and other findings were presented by Dr Karolina Benesova of the Department of Medicine V, Haematology, Oncology and Rheumatology, University Hospital in Heidelberg, Germany at the ESMO Virtual Congress 2020.

Dr Benesova discussed the occurrence and characteristics of rheumatic irAEs which have been associated with better tumour response following treatment with ICIs. She initiated the open-end TRheuMa registry, a prospective long-term observational study, to obtain real world data on patient characteristics and to determine the optimal clinical management of rheumatic irAEs. This study involves a patient cohort coping with rheumatic side effects of cancer therapies and is part of the large MalheuR project initiated in July 2018 at the University Hospital Heidelberg to explore interrelations of malignancies and RMDs.

TRheuMa registry provides real world data on rheumatic irAEs and patients outcome

By now, 65 patients have been recruited with a rheumatic irAE under ICI treatment; of these, 30 patients were treated with nivolumab, 33 with pembrolizumab, 12 patients with ipilimumab, 6 patients received treatment with a PD-L1 inhibitor and 10 patients received treatment with a combination of ICI agents.

The patient population comprised 47.7% of patients with NSCLC and 40.0% of patients with melanoma. In local cohorts of patients receiving ICI, 4.1% of NSCLC (n total=888) and 13.3% of melanoma (n total=195) developed a rheumatic irAE.

Flares of a pre-existing RMD were experienced by 15.4% of study patients and 9.2% of patients had an initial manifestation of a classical RMD. The de novo rheumatic irAEs primarily resembled the phenotypes of rheumatoid arthritis in 24.1% of patients, polymyalgia rheumatica in 16.7%, or spondyloarthritis in 46.3% of patients.

However, the de novo rheumatic irAEs presented with different laboratory findings, including mostly negative or unspecific autoantibodies and elevated CRP-levels in 77.4% of patients. On the basis of the clinical manifestations, CRP levels were often significantly higher than would be expected in classical RMDs and showed values >50 mg/L in 30.6% of patients.

Furthermore, 96.1% of the patients had signs of inflammation upon ultrasound examination with often symmetrical synovialitis and/or tenosynovialitis in the majority of cases.

According to a severity-based treatment algorithm developed by the investigators, therapy with ≤10 mg prednisone with/without NSAID was sufficient to resolve the irAEs in 53.8% of patients, but 15.4% required add-on cs-/bDMARD therapy. Ten (15.4%) patients discontinued ICI treatment temporarily or permanently due to the rheumatic irAE.

Registry-Findings-Highlight-the-Importance-of-Interdisciplinary-Care-in-Rheumatic-irAEs-1809O

Severity-based treatment algorithm of rheumatic irAEs: Interdisciplinarily developed treatment algorithm based on subtypes and severity of rheumatic immune-related adverse events (irAE) due to immune checkpoint inhibitors (ICI). § At level II, consultation of a rheumatologist should be considered. At level III and above, timely consultation of a rheumatologist is strongly recommended. * Add-on therapy with cs/bDMARDs (conventional synthetic (e. g. methotrexate) or biologic (e. g. TNFα-inhibitors) disease-modifying antirheumatic drugs) can take up to 8-12 weeks until onset of therapeutic response. Supportive therapy includes non-NSAID analgetics, physio- and ergotherapy.

© Karolina Benesova: Benesova K, et al. ESMO Open 2019, Nephrologe & Z Rheum 2020.

Interestingly, 48.0% of patients with a rheumatic irAE in this study compared with 4% of patients without an irAE in a historical control achieved complete remission of melanoma as best response and 45.8% of irAE-patients showed longstanding complete remission also as current outcome. In NSCLC patients, 69.0% reached a partial remission as best possible response.

Conclusions

According to the authors, these prospective real world data from the TRheuMa registry show that rheumatic irAEs mostly resemble classical RMDs with some distinct characteristics. Their clinical management strategy was effective and underlined a patient centred and interdisciplinary approach. Research on this immunological intersection between malignancies and RMDs offers the opportunity for better patient centred care and scientific progress.

The investigators future research agenda includes long-term observation of rheumatic irAEs and correlation with specific oncological outcomes.

Dr. Benesova is now supported by the medical faculty of the University of Heidelberg, Germany to advance the MalheuR project.

Reference

1809O – Benesova K, Diekmann L, Lorenz H-M, et al. TRheuMa registry provides real world data on rheumatic immune-related adverse events. ESMO Virtual Congress 2020.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Քաղցկեղն իմ համայնքում՝ Քաղցկեղով երեխաների բուժումը Հայաստանում

«Քաղցկեղն իմ համայնքում»-ը Cancer.Net Blog շարքից է, որը ցույց է տալիս աշխարհում քաղցկեղի ազդեցությունը և թե ինչպես են մարդիկ աշխատում իրենց տարածաշրջանում քաղցկեղով մարդկանց...

Ovarian cancer screening trial did not save lives

“The effort from the start was to save lives of women with ovarian cancer. To build evidence for a screening programme that the NHS...

Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical Carcinoma

Overall survival (OS) was significantly improved with cemiplimab as compared to investigator’s choice of chemotherapy in patients with recurrent/metastatic cervical cancer and progression after...

Expressive Writing, What is It?

One of psychotherapy’s main beliefs is that putting thoughts and feelings into words may produce mental health benefits. Of course, this also applies to cancer...

Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer

May 12, 2021, by NCI Staff In triple-negative breast cancer (TNBC), tumor cells don't have estrogen receptors (ER), progesterone receptors (PR), or large amounts of...

‘Will cancer make me infertile?’ – That Cancer Conversation

For the first episode of That Cancer Conversation, we explore infertility and cancer. From teenage body worries to an intercontinental surrogacy story, we chat to...